Literature DB >> 443343

Comparison of therapeutic routes in experimental Pseudomonas keratitis.

S D Davis, L D Sarff, R A Hyndiuk.   

Abstract

We determined the efficacy of tobramycin administered by topical, intramuscular, and subconjunctival routes in guinea pigs and rabbits with experimental Pseudomonas keratitis. The topical route of administration was consistently more effective than either subconjunctival or intramuscular routes. Subconjunctival injection of antibiotic did not enhance the effectiveness of topical therapy in either guinea pigs or rabbits. Intramuscular tobramycin was more effective than saline in guinea pigs with keratitis but not in rabbits with keratitis.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 443343     DOI: 10.1016/0002-9394(79)90309-x

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  6 in total

1.  Topical ocular antibiotics induce bacterial resistance at extraocular sites.

Authors:  B D Gaynor; J D Chidambaram; V Cevallos; Y Miao; K Miller; H C Jha; R C Bhatta; J S P Chaudhary; S Osaki Holm; J P Whitcher; K A Holbrook; A M Fry; T M Lietman
Journal:  Br J Ophthalmol       Date:  2005-09       Impact factor: 4.638

2.  Strategies for the management of microbial keratitis.

Authors:  B D Allan; J K Dart
Journal:  Br J Ophthalmol       Date:  1995-08       Impact factor: 4.638

Review 3.  Antibiotic therapy for ocular infection.

Authors:  R W Snyder; D B Glasser
Journal:  West J Med       Date:  1994-12

4.  Iontophoretic application of tobramycin to uninfected and Pseudomonas aeruginosa-infected rabbit corneas.

Authors:  J A Hobden; D S Rootman; R J O'Callaghan; J M Hill
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

Review 5.  Animal models of bacterial keratitis.

Authors:  Mary E Marquart
Journal:  J Biomed Biotechnol       Date:  2011-01-04

6.  Medical management approach to infectious keratitis.

Authors:  Nikhil S Gokhale
Journal:  Indian J Ophthalmol       Date:  2008 May-Jun       Impact factor: 1.848

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.